Synthetic biology has long relied on cell-based cloning to address the shortcomings of synthetic DNA. While an effective approach to isolate and amplify sequence-perfect DNA molecules from molecules containing synthesis errors, it has distinct limitations when it comes to producing complex structures such as lengthy DNA repeats or hairpins. Additionally, traditional cloning is a slow, multi-step workflow that carries the risk of contamination from bacterial gDNA and endotoxins.
Cell-free synthesis addresses these issues by completely eliminating cells from the workflow to manufacture highly repetitive or complex sequences rapidly from a manufacturing footprint roughly 10-fold smaller than cell-based processes.
In this GEN webinar, DNA synthesis experts Michael Junkin, PhD, and Brittany Enzmann, PhD, will provide an exclusive first look at Elegen’s GEN II Cell-Free DNA production platform that combines Elegen’s patented split-pool microfluidic synthesizer and cell-free cloning technology. Attendees will learn how the platform utilizes AI and robotics to fully automate the production of long, high-complexity, clonal-quality DNA—eliminating the need for bacterial cells and delivering high accuracy gene synthesis at a lower cost. Key learnings from the webinar include:
- Rapid, cell-free production of linear dsDNA up to 7 kb and plasmids up to 19 kb
- Real-time optimization of production protocols using LLMs
- Production of >10x more genes from a significantly reduced carbon footprint and lower capital costs in comparison to cell-based approaches
- Production of high accuracy, NGS-verified DNA at the price of low-quality gene fragments
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
